Effects of Combined Therapy With a Rho-Kinase Inhibitor and Prostacyclin on Monocrotaline-Induced Pulmonary Hypertension in Rats

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2007-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FJC.0b013e31806befe6PMID 17703136
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rho-kinase is an important therapeutic target in cardiovascular medicine.

  2009cited by this paper
• Ca2+-Independent, Inhibitory Effects of Cyclic Adenosine 5′-Monophosphate on Ca2+ Regulation of Phosphoinositide 3-Kinase C2α, Rho, and Myosin Phosphatase in Vascular Smooth Muscle

  2007cited by this paper
• Ca 2 (cid:1) -Independent, Inhibitory Effects of Cyclic Adenosine 5 (cid:2) -Monophosphate on Ca 2 (cid:1) Regulation of Phosphoinositide 3-Kinase C2 (cid:1) , Rho, and Myosin Phosphatase in Vascular Smooth Muscle

  2007cited by this paper
• Rho kinases in cardiovascular physiology and pathophysiology.

  2006cited by this paper
• Treatment of pulmonary arterial hypertension.

  2006cited by this paper
• Pulmonary Arterial Hypertension

  2006cited by this paper
• Long-Term Inhibition of Rho-kinase Ameliorates Hypoxia-Induced Pulmonary Hypertension in Mice

  2006cited by this paper
• Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension.

  2006influential reference
• Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.

  2005cited by this paper
• Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

  2005cited by this paper
• Prostacyclin Does Not Inhibit Rho-Kinase: An Implication for the Treatment of Pulmonary Hypertension

  2005cited by this paper
• Treatment of pulmonary arterial hypertension.

  2004cited by this paper
• Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats

  2004cited by this paper
• Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats.

  2004cited by this paper
• Pulmonary arterial hypertension.

  2004cited by this paper
• Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection

  2004cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• Prostanoid therapy for pulmonary arterial hypertension.

  2004cited by this paper
• A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats.

  2004cited by this paper
• Primary pulmonary hypertension.

  2003cited by this paper
• Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.

  2002cited by this paper
• A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats.

  2002cited by this paper
• Rho-Kinase Mediates Hypoxia-Induced Downregulation of Endothelial Nitric Oxide Synthase

  2002cited by this paper
• Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina

  2002cited by this paper
• Anti-anginal Effect of Fasudil, a Rho-Kinase Inhibitor, in Patients With Stable Effort Angina: A Multicenter Study

  2002cited by this paper
• Signal transduction by G‐proteins, Rho‐kinase and protein phosphatase to smooth muscle and non‐muscle myosin II

  2000cited by this paper
• Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor

  2000cited by this paper
• Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells

  2000cited by this paper
• Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm.

  1999cited by this paper
• Rho GTPases and the actin cytoskeleton.

  1998cited by this paper
• Primary pulmonary hypertension.

  1997cited by this paper
• Cytoskeletal Rearrangements and Transcriptional Activation of c-fos Serum Response Element by Rho-kinase*

  1997cited by this paper
• Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase

  1997cited by this paper
• Orally active prostacyclin analogue in primary pulmonary hypertension.

  1997cited by this paper
• Pulmonary hypertension: updating a mysterious disease.

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• The small GTP‐binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase.

  1996cited by this paper
• The small GTPase Rho: cellular functions and signal transduction.

  1996cited by this paper
• A Novel Serine/Threonine Kinase Binding the Ras-related RhoA GTPase Which Translocates the Kinase to Peripheral Membranes (*)

  1995cited by this paper
• Orally administered beraprost sodium inhibits pulmonary hypertension induced by monocrotaline in rats.

  1994cited by this paper
• Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension.

  1988cited by this paper
• Primary pulmonary hypertension.

  1987cited by this paper
• Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

  1978cited by this paper

• Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension—A Systematic Review

  2024cites this paper
• Effect of fasudil on clinical outcomes of pulmonary hypertension: a systematic review and meta-analysis

  2024cites this paper
• Pulmonary hypertension: Molecular aspects of current therapeutic intervention and future direction

  2018cites this paper
• Pharmacotherapy for Pulmonary Hypertension: Future Directions

  2017cites this paper
• Effects of fasudil on pulmonary hypertension in clinical practice.

  2017cites this paper
• Finding New Tricks for Old Drugs: Tumoricidal Activity of Non-Traditional Antitumor Drugs

  2016cites this paper
• Comparison of preventive effect of sildenafil and therapeutic effect of sildenafil treatment in rats with monocrotaline-induced pulmonary arterial hypertension

  2016cites this paper
• Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.

  2015cites this paper
• Synthesis and Isolation of Enantiomerically Enriched Cyclopenta[b]benzofurans Based on Products from Anodic Oxidation of 2,4‐Dimethylphenol

  2015cites this paper
• Molecular Biological Aspects, Therapeutic Targets and New Treatment Strategies

  2015cites this paper
• Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.

  2014cites this paper
• KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway

  2014cites this paper
• Concurrent Rho-Kinase and Tyrosine Kinase Platelet-Derived Growth Factor Inhibition in Experimental Pulmonary Hypertension

  2014cites this paper
• Targeted therapies in pulmonary arterial hypertension.

  2014cites this paper
• Vasodilatory Effect of a Novel Rho-Kinase Inhibitor, DL0805-2, on the rat Mesenteric Artery and its Potential Mechanisms

  2014cites this paper
• The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies

  2014cites this paper
• Drug Treatment of Pulmonary Hypertension in Children

  2014cites this paper
• Crucial Role of ROCK2 in Vascular Smooth Muscle Cells for Hypoxia-Induced Pulmonary Hypertension in Mice

  2013cites this paper
• Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.

  2013cites this paper
• Rho Kinases in Cardiovascular Physiology and Pathophysiology: The Effect of Fasudil

  2013cites this paper
• Drug Treatment of Pulmonary Hypertension in Children

  2013cites this paper
• Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.

  2013cites this paper
• Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension.

  2013cites this paper
• Rho-kinase inhibitors.

  2013cites this paper
• Role of Rho-kinase and its inhibitors in pulmonary hypertension.

  2013cites this paper
• The Beneficial Impact of Fasudil and Sildenafil on Monocrotaline-Induced Pulmonary Hypertension in Rats: A Hemodynamic and Biochemical Study

  2013cites this paper
• Implications de la voie RhoA/Rho-kinases dans la physiopathologie des atteintes vasculaires et interstitielles pulmonaires des maladies respiratoires chroniques : études humaines et expérimentales chez la souris

  2013cites this paper
• A Comprehensive Review: The Evolution of Animal Models in Pulmonary Hypertension Research; Are We there Yet?

  2013cites this paper
• Animal models of pulmonary hypertension: Rho kinase inhibition.

  2012cites this paper
• [Development of Rho kinase inhibitors for pulmonary arterial hypertension].

  2012cites this paper
• The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally

  2012cites this paper
• Recent progress in the management of pulmonary hypertension.

  2011cites this paper
• Intralipid Prevents and Rescues Fatal Pulmonary Arterial Hypertension and Right Ventricular Failure in Rats

  2011cites this paper
• Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence

  2010cites this paper
• Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension.

  2010cites this paper
• Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil

  2010cites this paper
• Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype

  2010cites this paper
• Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension

  2010cites this paper
• Novel Approaches to Treat Experimental Pulmonary Arterial Hypertension: A Review

  2010cites this paper
• Pharmacological targets for pulmonary vascular disease: vasodilation versus anti-remodelling.

  2010cites this paper
• Role of Rho kinase in sphingosine 1-phosphate-mediated endothelial and smooth muscle cell migration and differentiation

  2010cites this paper
• New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation

  2010cites this paper
• Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats.

  2010cites this paper
• Identification of new prognostic factors of pulmonary hypertension.

  2010cites this paper
• Novel approaches to treat pulmonary arterial hypertension

  2009cites this paper
• Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure.

  2009cites this paper
• Molecular and cellular characterization of cardiac overload-induced hypertrophy and failure

  2009cites this paper
• Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension.

  2009cites this paper
• Therapeutic targets in pulmonary arterial hypertension.

  2009cites this paper
• Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension

  2008cites this paper
• Pulmonary hypertension: therapeutic targets within the serotonin system

  2008cites this paper